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1 Introduction
In 1991, Mark Weiser predicted that the technology that most inﬂuences us is the technology that disappears
before our eyes and weaves itself completely into our everyday lives (Weiser 1991). Almost a quarter of a
century later, we already rely on such developments on a daily basis: smartphones, tablets, smart watches
and data glasses; what is on offer is growing with the miniaturisation of technology. Basically, these devices
are high-performance computers “en miniature” and they are either incorporated into, or even created as,
everyday objects. The market is not only growing for these devices, but also for the software with which
they operate. Increasingly, platforms are being created whereby third parties can provide their own computer
programs which are commonly referred to as “apps”.
Mobile devices and apps are also ﬁnding their way into the health sector. “mHealth” (mobile health) is in-
tegrated into a wide range of health services which are offered on portable mobile devices. Health apps on
smartphones and tablets are themost popular type of application in this ﬁeld. There are numerous possibilities
for using health-related apps and they range from comparatively simple ﬁtness and wellness apps to applica-
tions providing sophisticated diagnostics and treatment options. The target audience is as diverse as the range
of applications being offered: relevant apps are used not only by patients and insurance companies, but also by
healthcare professionals. Health apps already play an important role in the secondary healthcare market, but
are also gaining importance for the primary healthcare market, where patient services are reimbursed through
statutory (GKV) and private health insurance (PKV).
Overall, various economic and political stakeholders, as well as users – on a national and international level
– see great potential for this new technology for healthcare accompanied by growth in the digital economy.
Hopes of improving healthcare through cost-effectivemeasures are to bemet by implementingmHealth (Becker
et al. 2014). A possible starting point can be measures in the context of prevention, which provide a cost-
effective means for promoting self-help and patient autonomy (Landry 2015, Boulos 2011). As a consequence
of the recently adopted Prevention Act, in Germany, support for health related self-help has been increased,
which also promotes the discussion about mHealth based solutions.
The optimisation of care for chronically ill patients is also being identiﬁed as a possibly effective ﬁeld of appli-
cation. In particular, potential for success is seen for treatment monitoring models and measures to improve
adherence to treatment (Becker et al. 2012). The same applies to post-operative care and rehabilitation. For
structurally weak regions with only few health care professionals, digital solutions may offer support for pro-
viding or receiving care, independent of location (Anderson, Henner and Burkey 2013). On the whole, mHealth
has the potential to improve patients’/insured people’s health literacy which may allow them to exercise their
patient rights more easily.
However, new apps can also confuse users, fail to provide correct information or may create a false sense
of security. So far, risks have only been insufﬁciently studied. Knowledge of hazards and health risks is,
however, essential for weighing up the risks against the beneﬁts. Regarding this latter point, medico-ethical
considerations are also to be taken into account, and these deal with issues of autonomy, participation, privacy
and monitoring in the context of the use of health apps.
2 Problem Deﬁnition
The rapid and enthusiastically greeted spread of mobile technologies in medicine has so far resulted in a pro-
liferation of methods. Many projects are geared to short-term successes and have so far been done without a
long-term strategic orientation. This multifaceted complexity for everyone involved makes it difﬁcult to as-
sess the opportunities and risks, particularly because a solid base of information is currently lacking (Albrecht
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2013, Nurul and Albrecht 2014). The lack of extensive scientiﬁc evidence regarding the long-term beneﬁts of
mobile solutions in the above ﬁelds is often criticised (van Heerden, Tomlinson and Swartz 2012). Existing
studies greatly vary in terms of both methods and content, making a comparison of the results as well as their
transferability to other situations (Free et al. 2013, Free et al. 2013a) and possible reimbursement of costs
more difﬁcult. The new opportunities arising from the technology may equally be underestimated or overes-
timated. Measures which are based on an insufﬁciently valid foundation run the risk of the available control
mechanisms being inadequately aligned. This can adversely affect care (beyond the needs), security (measures
that are too relaxed) or can hamper innovation (measures that are too strict).
Creating a base of evidence may help reduce the barriers for adopting new legislation and facilitate the neces-
sary interdisciplinary cooperation, ultimately improving the quality of patient care. The current lack of a base
of evidence on the subject of mHealth is a global problem. There are only few independent studies, and often,
available personnel capacities are insufﬁcient for meeting the demand for scientiﬁcally sound analysis. This
results in a lack of orientation, which, amongst other things, leads to insufﬁciently adapted legal requirements
for new mHealth technology and thus complicates or misdirects innovations. This also has an impact on Ger-
many as a business location. A market research ﬁrm advises, for example, that mHealth products should only
be developed for the German market with low priority (research2guidance 2015), in part because electronic
prescriptions are not possible, there is a lack of infrastructure for electronic health records, and professional
laws only allow for remote care in a limited set of circumstances.
3 Objective
The aim of the project “Chances and Risks of Mobile Health Apps (CHARISMHA)” was to take stock of the cur-
rent framework for the use of health apps in Germany in the context of efforts made by other EU countries.
The objective was to identify ﬁelds of action for promoting meaningful use and recommend measures to min-
imise risks. The exploration of the ﬁeld needed to include a variety of disciplines (e.g. medicine, economics,
law, ethics, see below). Existing regulations, which are usually not speciﬁcally adapted to the requirements
of mobile technologies, had to be examined via a multidisciplinary approach with regard to their strengths,
weaknesses, opportunities and risks. Using input from various disciplines, potential solutions needed to be
developed, and these are intended to serve as a basis for adapting the legal frameworks and initiating targeted
funding programmes as well as incentive schemes.
4 Method
The study¹ was based on a catalogue of key subjects and questions, which was derived from the general discus-
sion on the topic and supplemented with suggestions from the Federal Ministry of Health (BMG). Answering
these questions required a broad, ﬂexible and interdisciplinary approach, not least of all due to the rapid,
scarcely regulated developments, as well as overwhelming and yet confusing media coverage. Various inter-
faces and intersections between the different specialist disciplines had to be taken into account in order to
uncover and understand the complex dynamics and synergisms/constraints of the existing complex relation-
ships. The work was carried out by an interdisciplinary team of experts.
Each expert worked independently on the particular aspects relating to her or his discipline and used the sci-
entiﬁc methods such as structured literature reviews and other tools. The respective partial results, also con-
taining initial conclusions and recommendations in addition to the analysis, were immediately made available
to all team members. In ﬁve coordination workshops, existing results were presented and comprehensively
discussed in order to adequately consider the relevant interfaces and to close any gaps in the content. Smaller
teams were formed to work intensively on speciﬁc overarching issues. Conclusions and recommendations were
jointly discussed and coordinated.
The results were summarised in a preliminary ﬁnal report and made available to various stakeholders with an
invitation to comment within four weeks. At the beginning of the project, the representatives were invited
and informed about the planned stock taking and were invited to participate in the comment phase of the
project. The feedback was collected and its relevance to the report was jointly evaluated by the experts, with
¹ Chronological sequence: the study period spanned eight months, beginning on 15/08/2015 and ending on 15/04/2016. The
study was drawn up 03/02/2016 and released for the four-week comment period, beginning on 08/03/2016. A total of ﬁve
consultation workshops were held at four-weekly intervals. The ﬁnal report was ﬁnalised on 15/04/2016 after processing the
feedback.
Rationale j 3
errors corrected in the report and relevant aspects being included in the conclusions. Lastly, the report was
ﬁnalised and published as a result. Available comments on the study are provided on the project’s website
(http://www.charismha.de/).
5 Financing
The study was funded by the German Federal Ministry of Health (BMG) under the grant number ZMV I 1 -
2515FSB503. The total amount was EUR 103,690.30, which takes into account the own contribution of the
Medizinische Hochschule Hannover (Hannover Medical School).
6 Structure
The results are presented in a chapter structure as explained below.
The ﬁrst section (Chapter 1, “Introduction and Deﬁnition of Terms”) ﬁrst establishes the subject of electroni-
cally supported health (eHealth) and the contribution made by mobile technology (mHealth) in this context.
Then, the multifaceted concept of health apps is set out, taking into account the underlying technology and
the stakeholders involved (manufacturers, users). The following section provides a description of the market
(Chapter 2, “Health Apps and Market”). Policy frameworks are described in Chapter 3 (“Health Apps and Politi-
cal Framework”). Chapter 4 analyses general challenges arising from the use of this technology with regard to
care, with a special focus on the challenges arising from the use of apps in (rural) care settings and from the
requirements of speciﬁc user groups with special needs, such as the chronically ill (Chapter 4, “Health Apps
and Challenges”). In the subsequent chapters, the greatest potentials for individual ﬁelds of application in
the context of prevention (Chapter 5, “Health Apps and Prevention”), diagnostics and treatment (Chapter 6,
“Health Apps and Diagnostics and Treatment”), as well as (healthcare) research (Chapter 7, “Health Apps in
the Context of Research”) are worked out in detail. After describing the opportunities arising from the use of
health apps, the risks are considered in Chapter 8 (“Health Apps and Risks”). Here, in addition to discussing
the concepts of damage, hazards and risks, risks arising from the use of apps in a medical context are con-
sidered and assessed for all user groups (the health-conscious, patients, professional users). Ethical aspects
users and manufacturers are confronted with are described in Chapter 9 (“Health Apps and Ethics”).
The subsequent chapters describe the legal frameworks in relation to the demands of data protection and lia-
bility (Chapter 10, “Health Apps and Data Protection”), as well as regulatory requirements and legal provisions
(Chapter 11, “Health Apps as Medical Devices”).
In particular, statutory health insurance companies operate in a very rigid legal framework and must comply
with multiple regulations in order to guarantee healthcare. To manufacturers of health apps, this market is
very appealing. Offers that are reimbursed/funded by insurers beneﬁt those who are insured. Therefore, a
separate chapter is devoted to the analysis of the market situation, the reimbursement possibilities and the
effects and incentives for statutory and private health insurance: Chapter 12 (“Health Apps in Statutory and
Private Health Insurance”) tackles the evaluation and analysis of health apps offered by private and statutory
health insurance. The speciﬁcs to be considered in this context, as well as the presentation of reimbursement
methods of apps by the payers are looked at in particular here.
Due to the low prerequisites for developing health apps and the low thresholds for access to the market through
simple cross-border sales processes, users are confronted with a highly dynamic and scarcely regulated market
situation. In the subsequent chapters, guidance for patients/insured persons (Chapter 13, “Orientation for
Users of Health Apps”) and professional users (Chapter 14, “Orientation for Professional Users of Health Apps”),
as well as for manufacturers (Chapter 15, “Orientation for Manufacturers of Health Apps”) is compiled, taking
into account the insights gained previously.
Sections of each chapter contain conclusions naming possible ﬁelds of action for policymakers and stakehold-
ers in the health care sector and highlight options for actions and recommendations for further actions based
on the ﬁndings for the respective topics.
7 Summary
The presented work is meant to provide insights into current developments and trends with respect to the
use of mobile health apps. A special emphasis shall be placed on the areas of prevention, diagnostics and
therapy as well as healthcare in general, for example regarding the care for patients with chronic conditions,
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elderly people or rural populations. Other important areas of interest are the identiﬁcation of risks that may
arise from using health apps, especially in the context of data protection and data security. An appraisal of
the practical, as well as regulatory hurdles one may encounter when using health-related apps in various use
cases is given along with a description of points where adaptations to existing regulations might be advised.
In addition, the ethical implications of using health-related apps in various contexts are outlined. In order
to better respond to the needs of individual stakeholders, i.e. patients as well as medical professionals and
developers of health apps, an outline of possible ways to support each of these groups is provided. Finally, the
closing summary chapter describes important areas where action may be advised to be able to eliminate the
identiﬁed hurdles, which may be technical in nature, but may also be due to legal or ethical concerns. This
aims at minimising potential risks for all those who are dealing with health related apps, but may also serve to
provide insights into how relevant uses of mobile technologies in health contexts can be promoted.
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